Latest Breaking News On - Jeroen rovers - Page 1 : comparemela.com

Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023

Press Release Stockholm, Sweden, December 11, 2023 As of November 24, 2023, median relapse-free survival stood at 30.4 months Median overall survival was not reached, with the majority of.

Noord hollandSan diegoUnited statesErik mantingAmerican society of hematologyLymphoma groupPress releaseAmerican societyAnnual meetingPrincipal investigatorCalifornia decemberJeroen roversAustralian leukaemiaNasdaq stockholmOrphan drug designationFast track designation

Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023

Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoNoord hollandErik mantingAmerican society of hematologyLymphoma groupPress releaseAmerican societyAnnual meetingPrincipal investigatorCalifornia decemberJeroen roversAustralian leukaemiaNasdaq stockholmOrphan drug designationFast track designation

Mendus And Australasian Leukaemia & Lymphoma Group To Expand Clinical Testing Of Vididencel As Maintenance Treatment For AML

Mendus And Australasian Leukaemia & Lymphoma Group To Expand Clinical Testing Of Vididencel As Maintenance Treatment For AML
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesErik mantingAndrew weiAustralasian leukaemia lymphoma groupPeter maccallum cancer centreNasdaq pressAmerican society of hematology conferenceAmerican society of hematologyAustralasian leukaemiaLymphoma groupJeroen roversChief medical officerProfessor dr andrew weiAcute myeloid leukemiaRoyal melbourne hospitalAmerican society

Mendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023

Mendus presents updated ALISON clinical trial data for vididencel in ovarian cancer at SITC 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesErik mantingAmerican society of hematologySociety for immunotherapy of cancerAnnual meetingJeroen roversChief medical officerNasdaq stockholmAmerican societyOrphan drug designationFast track designationNorthx biologics

Mendus Phase 1 vididencel clinical trial results in AML and high-risk MDS patients published in peer-reviewed medical journal

Press Release Stockholm, Sweden, November 3, 2023 Mendus Phase 1 vididencel clinical trial results in AML and high-risk MDS patients published in peer-reviewed medical journal Publication.

Noord hollandUnited statesErik mantingCancer center amsterdamAmerican society of hematologyErasmus university medical centerHigh risk myelodysplastic syndromeAcute myeloid leukemia patients receivingPrincipal investigatorJeroen roversChief medical officerNasdaq stockholmAmerican societyOrphan drug designationFast track designationNorthx biologics